Literature DB >> 20200431

Long-term mortality from second malignant neoplasms in 5-year survivors of solid childhood tumors: temporal pattern of risk according to type of treatment.

Markhaba Tukenova1, Ibrahima Diallo, Mike Hawkins, Catherine Guibout, Eric Quiniou, Hélène Pacquement, Frederic Dhermain, Akhtar Shamsaldin, Odile Oberlin, Florent de Vathaire.   

Abstract

BACKGROUND: The temporal pattern in mortality from late second malignant neoplasms in solid childhood cancer survivors, according to the type of treatment, has not been investigated in detail.
METHODS: We studied 4,230 5-year survivors of solid childhood cancer diagnosed between 1942 and 1986 in France and the United Kingdom. Complete clinical, chemotherapy, and radiotherapy data were recorded and the integral radiation dose was estimated for 2,701 of the 2,948 patients who had received radiotherapy.
RESULTS: After a median follow-up of 28 years, 134 fatal events were due to second malignancies, compared with the 13.3 expected from the general France-UK population rates. The standardized mortality ratio was of a similar magnitude after radiotherapy alone and chemotherapy alone and higher after both treatments. The standardized mortality ratio decreased with follow-up, whereas the absolute excess risk increased significantly over a period of at least 25 years after the first cancer. This temporal pattern was similar after chemotherapy alone, radiotherapy alone, or both treatments. We observed a similar long-term temporal pattern among survivors who had died of a second malignant neoplasm of the gastrointestinal tract and breast. Survivors who had received a higher integral radiation dose during radiotherapy were at a particularly high risk, as well as those who had received alkylating agents and epipodophyllotoxins.
CONCLUSIONS: Five-year survivors of childhood cancer run a high long-term mortality risk for all types of second malignant neoplasms whatever the treatment received and require careful long-term screening well beyond 25 years after the diagnosis.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20200431     DOI: 10.1158/1055-9965.EPI-09-1156

Source DB:  PubMed          Journal:  Cancer Epidemiol Biomarkers Prev        ISSN: 1055-9965            Impact factor:   4.254


  12 in total

1.  Cardiovascular effects after low-dose exposure and radiotherapy: what research is needed?

Authors:  Jan Wondergem; Marjan Boerma; Kazunori Kodama; Fiona A Stewart; Klaus R Trott
Journal:  Radiat Environ Biophys       Date:  2013-09-03       Impact factor: 1.925

2.  Pediatric Hodgkin lymphoma: trade-offs between short- and long-term mortality risks.

Authors:  Jennifer M Yeh; Lisa Diller
Journal:  Blood       Date:  2012-07-23       Impact factor: 22.113

3.  Clinical and histological features of second breast cancers following radiotherapy for childhood and young adult malignancy.

Authors:  Charlotte Demoor-Goldschmidt; Stéphane Supiot; Marc-André Mahé; Odile Oberlin; Rodrigue Allodji; Nadia Haddy; Sylvie Helfre; Céline Vigneron; Victoire Brillaud-Meflah; Valérie Bernier; Anne Laprie; Anne Ducassou; Line Claude; Ibrahim Diallo; Florent de Vathaire
Journal:  Br J Radiol       Date:  2018-03-15       Impact factor: 3.039

4.  Noncancer-related mortality risks in adult survivors of pediatric malignancies: the childhood cancer survivor study.

Authors:  Cheryl L Cox; Vikki G Nolan; Wendy Leisenring; Yutaka Yasui; Susan W Ogg; Ann C Mertens; Joseph P Neglia; Kirsten K Ness; Gregory T Armstrong; Les L Robison
Journal:  J Cancer Surviv       Date:  2014-04-10       Impact factor: 4.442

Review 5.  Subsequent neoplasms of the CNS among survivors of childhood cancer: a systematic review.

Authors:  Daniel C Bowers; Paul C Nathan; Louis Constine; Catherine Woodman; Smita Bhatia; Karen Keller; Lisa Bashore
Journal:  Lancet Oncol       Date:  2013-07       Impact factor: 41.316

6.  The cyclophosphamide equivalent dose as an approach for quantifying alkylating agent exposure: a report from the Childhood Cancer Survivor Study.

Authors:  Daniel M Green; Vikki G Nolan; Pamela J Goodman; John A Whitton; DeoKumar Srivastava; Wendy M Leisenring; Joseph P Neglia; Charles A Sklar; Sue C Kaste; Melissa M Hudson; Lisa R Diller; Marilyn Stovall; Sarah S Donaldson; Leslie L Robison
Journal:  Pediatr Blood Cancer       Date:  2013-08-12       Impact factor: 3.167

Review 7.  Review of risk factors of secondary cancers among cancer survivors.

Authors:  Charlotte Demoor-Goldschmidt; Florent de Vathaire
Journal:  Br J Radiol       Date:  2018-09-12       Impact factor: 3.039

8.  Survival disparities for second primary malignancies diagnosed among childhood cancer survivors: A population-based assessment.

Authors:  Austin L Brown; Vidal M Arroyo; Jennifer E Agrusa; Michael E Scheurer; M Monica Gramatges; Philip J Lupo
Journal:  Cancer       Date:  2019-06-28       Impact factor: 6.860

9.  Risk of second malignancies in patients with early-stage classical Hodgkin's lymphoma treated in a modern era.

Authors:  Melissa H LeMieux; Abhishek A Solanki; Usama Mahmood; Steven J Chmura; Matthew Koshy
Journal:  Cancer Med       Date:  2015-01-26       Impact factor: 4.452

10.  Second salvage treatment for local recurrence of prostate cancer using high-dose-rate brachytherapy: a case report.

Authors:  Audrey Claren; Mathieu Gautier; Julien Feuillade; Alexander Tuan Falk; Jean-Michel Hannoun Levi
Journal:  J Contemp Brachytherapy       Date:  2015-05-28
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.